Last checked at 19 Dec 2022 12:01
Renalytix plc
("Renalytix" or the "Company")
Result of AGM
LONDON and SALT LAKE, 19 December 2022 - Renalytix (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.
The results of the AGM are detailed below:
Resolution | In Favour |
| Against |
| Withheld | ||
| Votes | % |
| Votes | % |
| Votes |
1 | 36,757,852 | 99.87% |
| 48,952 | 0.13% |
| 9,492 |
2 | 29,678,455 | 80.64% |
| 7,125,845 | 19.36% |
| 11,996 |
3 | 28,811,868 | 93.45% |
| 2,019,388 | 6.55% |
| 5,985,040 |
4 | 36,062,793 | 97.97% |
| 747,409 | 2.03% |
| 6,094 |
5 | 36,057,816 | 97.95% |
| 753,695 | 2.05% |
| 4,785 |
6 | 30,523,447 | 82.92% |
| 6,285,397 | 17.08% |
| 7,452 |
7 | 36,705,602 | 99.72% |
| 102,842 | 0.28% |
| 7,852 |
8 | 36,733,085 | 99.78% |
| 79,463 | 0.22% |
| 3,748 |
9 | 36,744,286 | 99.81% |
| 69,330 | 0.19% |
| 2,680 |
10 | 36,708,920 | 99.75% |
| 92,058 | 0.25% |
| 15,318 |
For further information, please contact:
Renalytix plc | www.renalytix.com | |
James McCullough, CEO | Via Walbrook PR | |
Stifel (Nominated Adviser, Joint Broker) | Tel: 020 7710 7600 | |
Alex Price / Nicholas Moore | ||
Investec Bank plc (Joint Broker) | Tel: 020 7597 4000 | |
Gary Clarence / Daniel Adams | ||
Walbrook PR Limited | Tel: 020 7933 8780 or renalytix@walbrookpr.com | |
Paul McManus / Alice Woodings | Mob: 07980 541 893 / 07407 804 654 | |
About KidneyIntelX™
KidneyIntelX™ is a laboratory developed test demonstrated to be a reliable, bioprognostic™ methodology that yields a simple-to-understand, custom risk score, enabling prediction of which adult patients with T2D and early CKD (stages 1-3) are at low, intermediate or high risk for rapid progressive decline in kidney function. By combining information from KidneyIntelX with newer cardio- and reno-protective therapies, doctors will have more information in determining which patients are at higher versus lower risk for rapid disease progression and may be able to more appropriately target resources and guideline-recommended treatments to advance kidney health. KidneyIntelX is supported by a growing body of clinical, utility and health economic studies (including a validation study of two large cohorts) and has a demonstrated a 72% improvement in predicting those patients who are at high risk for rapid progressive decline in kidney function versus the current standard of care (eGFR and UACR). KidneyIntelX has received Breakthrough Device Designation from the U.S. Food and Drug Administration and Renalytix has submitted for De Novo marketing authorization. To learn more about KidneyIntelX and review the evidence, visit www.kidneyintelx.com.
About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that enables early-stage chronic kidney disease progression risk assessment. The Company's lead product, KidneyIntelX™, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.